Practical, regulatory and clinical considerations for development of inhalation drug products

14Citations
Citations of this article
88Readers
Mendeley users who have this article in their library.

Abstract

The formulation and device collectively constitute an inhalation drug product. Development of inhaled drugs must consider the compatibility between formulation and device in order to achieve the intended pharmaceutical performance and usability of the product to improve patient compliance with treatment instruction. From the points of formulation, device and patient use, this article summarizes the inhalation drugs, including pressurized metered dose inhaler (pMDI), dry powder inhaler (DPI), and nebulizer that are currently available in the US and UK markets. It also discusses the practical considerations for the development of inhalers and provides an update on the corresponding regulations of the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency).

Cite

CITATION STYLE

APA

Hou, S., Wu, J., Li, X., & Shu, H. (2015, December 1). Practical, regulatory and clinical considerations for development of inhalation drug products. Asian Journal of Pharmaceutical Sciences. Shenyang Pharmaceutical University. https://doi.org/10.1016/j.ajps.2015.08.008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free